Intrahepatic cholangiocellular carcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Aged >=18 years, male or female; 2.Patients with intrahepatic cholangiocarcinoma confirmed by histological or cytological examination; 3.Inoperable patients,Postoperative recurrence and cannot be re-operated,Relapsed or residual after RFA/TACE treatment and unreoperable; 4.Measurable lesions conforming to RECIST 1.1, RECIST, and IRECIST standards; 5.Use ICIs plus tyrosine kinase inhibitor; 6.At least one follow-up imaging assessment.
Exclusion criteria
Exclusion criteria: 1.Patients with hepatocellular carcinoma, mixed cell carcinoma or fibrotic laminar cell carcinoma diagnosed pathologically; 2.Patients with previous or concurrent malignancies (except for skin basal cell carcinoma, prostate cancer in situ and cervical carcinoma in situ); 3.Patients with a history of psychotropic substance abuse and unable to quit or with mental disorders; 4.Patients with any active autoimmune disease or history of autoimmune disease (such as, but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis; subjects who need bronchodilator for medical intervention cannot be included); but the following patients are allowed to be included: vitiligo, psoriasis, alopecia, control group without systemic treatment Patients with type I diabetes were treated with replacement therapy for hypothyroidism with normal thyroid function; 5.According to the researchers' judgment, there were other patients who were not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progress free survival;overall survival;rate of adverse reaction; | — |
Countries
China
Contacts
Zhongda Hospital of Southeast University